Caris Life Sciences, Inc. (CAI) Coverage Begins at Neutral as Piper Cites Need for Growth Acceleration

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Caris Life Sciences, Inc. is among the best biotech stocks

TheFly reported on April 10 that Piper Sandler began coverage of CAI with a Neutral rating and a $21 price target. The firm highlighted the company’s combination of strong scientific capabilities and relatively stable financial profile compared to many peers in the space. It projected revenue growth of around 20% over the next few years but indicated that further acceleration in therapy selection services, potentially driven by Salesforce expansion or new product offerings, would be needed before adopting a more positive stance on the stock.

In a significant operational development, on April 1, Caris Life Sciences, Inc. (NASDAQ:CAI) introduced Caris ChromoSeq, a new genomic testing platform combining whole genome and whole transcriptome sequencing to evaluate myeloid cancers. The assay is designed for conditions such as acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, as well as cases with persistent unexplained cytopenia.

Caris Life Sciences, Inc. (CAI) Coverage Begins at Neutral as Piper Cites Need for Growth Acceleration

It enables comprehensive detection of mutations, structural changes, and chromosomal abnormalities through a single test, reducing the need for multiple diagnostic procedures. The platform delivers in-depth genomic data and integrates findings into a unified report, supporting faster and more informed clinical decisions. Results are expected within approximately seven days, improving efficiency in patient care.

Caris Life Sciences, Inc. (NASDAQ:CAI) is an AI-driven precision medicine company that uses large-scale clinico-genomic data and molecular profiling to guide cancer diagnosis and treatment. Its platforms apply machine learning to predict therapy response and improve personalized oncology outcomes.

While we acknowledge the risk and potential of CAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Most Undervalued Healthcare Stocks to Buy Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.